EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0MH6: Ipsen SA

12 Nov 2025
LAST:

130.1

CHANGE:
 0.15		OPEN:
130.2		HIGH:
130.8		ASK:
115.5		VOLUME:
100
CHG(%):
0.12		PREV:
129.9		LOW:
129.8		BID:
109.9		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Nov 25130.2130.8129.8130.1100
11 Nov 25127.0130.2126.8129.920.7K
10 Nov 25124.1127.7123.8127.347
07 Nov 25123.0123.3122.8122.95.5K
06 Nov 25123.1123.1122.6122.74.2K
05 Nov 25123.8124.6123.1123.1825
04 Nov 25122.8123.7121.7123.62.6K
03 Nov 25121.8122.8121.7122.4248
31 Oct 25122.5122.6121.7122.2100
30 Oct 25121.4122.4121.1121.8100

COMPANY PROFILE

Name:Ipsen SA
About:Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Address:65, quai Georges Gorse, Boulogne-Billancourt, France, 92100
Website:https://www.ipsen.com
ISIN:FR0010259150
LEI:549300M6SGDPB4Z94P11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:25.32 
Price to Sales:3.34 
Price to Book:3.00 
Profit Margin:0.14 
Operating Margin:0.27 
Return on Assets:0.09 
Return on Equity:0.13 
DivYield:0.02 
Div/Share:1.40 
Revenue:3.282B 
EBITDA:1.377B 

TECHNICAL INDICATORS

MA5:126.552.8%
MA10:124.574.4%
MA20:121.137.4%
MA50:118.2510.0%
MA100:113.6314.5%
MA200:109.6318.6%
STO9:91.28 
STO14:93.56 
RSI14:78.83 
MTM14:8.55
ROC14:0.07 
ATR:1.80 
Week High:130.800.6%
Week Low:122.606.1%
Month High:130.800.6%
Month Low:113.2018.6%
Year High:130.800.6%
Year Low:88.0547.7%
Volatility:22.48 

RECENT SPLITS

Date Ratio
01 Jun 20102-1

RECENT DIVIDENDS

Date Amount
04 Jun 2025$1.40
30 May 2024$1.20
02 Jun 2023$1.20
31 May 2022$1.20
31 May 2021$1.00
28 May 2021$1.00
03 Jun 2020$1.00
31 May 2019$1.00
04 Jun 2018$1.00
09 Jun 2017$0.85